Download presentation
Presentation is loading. Please wait.
Published byCoralie St-Denis Modified over 6 years ago
1
Reduced High-density Lipoprotein Cholesterol in Patients Receiving Rosiglitazone and Fenofibrate
Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD The American Journal of Medicine Volume 121, Issue 10, Pages e3-e4 (October 2008) DOI: /j.amjmed Copyright © 2008 Elsevier Inc. Terms and Conditions
2
Figure 1 Variation of serum HDL-C levels during therapy. The arrow (←) indicates cessation of rosiglitazone (patients 1 and 2) or fenofibrate (patient 3). HDL-C=high-density lipoprotein C. The American Journal of Medicine , e3-e4DOI: ( /j.amjmed ) Copyright © 2008 Elsevier Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.